Live Announcement Nov 04, 2026

Thyrocare Q2 FY27 Results: Revenue Up 25% to ₹270 Crore on Strong Pathology Growth

Home » Live Updates & Media » Thyrocare Q2 FY27 Results: Revenue…
Thyrocare Q2 FY27 Results: Revenue Up 25% to ₹270 Crore on Strong Pathology Growth

The Thyrocare Q2 FY27 results show a strong quarter for one of India’s largest diagnostic chains. For the quarter ended September 2026, consolidated revenue grew 25.1% year on year to ₹270.08 crore, driven mainly by its core pathology business. The company also processed a record 61.6 million tests and widened its specialty diagnostics range.

Thyrocare Q2 FY27 Results: Key Financial Highlights

Here is how the numbers looked for the July–September 2026 quarter:

  • Consolidated revenue: ₹270.08 crore, up 25.1% year on year.
  • EBITDA: ₹89.3 crore, up 24.9% year on year.
  • Profit after tax (before exceptional items): ₹60.2 crore, up 25.7%.
  • Profit after tax (after exceptional items): ₹15.2 crore.

Why Profit After Tax Looks Lower: The ₹45 Crore Exceptional Item

The gap between the two profit figures comes from a one-time, non-cash impairment charge of ₹45 crore. It relates to the proposed sale of Thyrocare’s radiology arm, Nueclear Healthcare Limited. The company has clarified that this charge does not affect its day-to-day operational performance, so the operating picture remains strong.

Pathology Drives Growth: Franchise and Partnership Segments

Pathology was the main growth engine this quarter. Franchise revenue grew 26.9% year on year, while the partnership segment grew 27.9%. Test volumes rose 27.4% to 61.6 million, which Thyrocare says makes it the largest diagnostic test volume processor in India.

New Specialty Diagnostics: Allergy, Genomics and Pregnancy Test Kit

Thyrocare is moving beyond routine blood tests. Having entered allergy and genomics testing last quarter, it has now launched NIPT (non-invasive prenatal testing), with its test menu set to expand in phases. It also introduced a Pregnancy Test Kit backed by a confirmatory lab test, which the company describes as a first in India. The kit was developed with Ascent, a group company under API Holdings, and is already available in more than 10,000 chemist outlets.

Managing Director and CEO Rahul Guha said the company is also entering Point of Care devices and hopes to be present in all major chemist outlets soon. To learn how modern diagnostics fit into preventive care, read our guide on diagnostic services and health testing, or contact our specialists for guidance.

What the Thyrocare Q2 FY27 Results Mean for the Diagnostics Sector

The numbers point to rising demand for affordable, high-volume testing across India, especially in underserved regions where franchise and partner networks are expanding. Growth in specialty segments such as genomics and allergy testing also suggests that diagnostic chains are building higher-value services alongside routine pathology. You can read the original report on ET HealthWorld and explore the company’s services on the official Thyrocare website.

Frequently Asked Questions

What was Thyrocare’s revenue in Q2 FY27?

  • Thyrocare reported consolidated revenue of ₹270.08 crore in Q2 FY27, a 25.1% increase over the same quarter last year.

What was Thyrocare’s profit after tax in Q2 FY27?

  • Profit after tax before exceptional items was ₹60.2 crore, up 25.7%. After a ₹45 crore one-time impairment charge, profit after tax stood at ₹15.2 crore.

Why did Thyrocare record a ₹45 crore exceptional charge?

  • It is a one-time, non-cash impairment linked to the proposed sale of its radiology arm, Nueclear Healthcare Limited. The company says it has no impact on operational performance.

How many tests did Thyrocare process in Q2 FY27?

  • Thyrocare processed 61.6 million tests, up 27.4% year on year.

What new products did Thyrocare launch this quarter?

  • It launched NIPT for genomics, expanded allergy testing, and introduced a Pregnancy Test Kit backed by a confirmatory lab test, available in over 10,000 chemists.

Looking for Diagnostic Solutions?

Connect with our technical team for institutional supplies and clinical product inquiries.

Scroll to Top